ARA-290 Reconstitution Guide for Laboratory Research

Peptides are shipped and stored in lyophilized form because removing water from the formulation eliminates the hydrolytic and oxidative pathways that require an aqueous environment. A dry, sealed vial of ARA-290 kept at the correct temperature is far more stable over weeks or months than the same material would be in solution. The tradeoff is that lyophilized powder cannot be pipetted, diluted, or added to an assay directly; it has to be dissolved into a known volume of solvent first so that a defined concentration can be calculated and used.

Reconstitution is the step that converts a fixed mass of freeze-dried peptide into a liquid stock solution with a known concentration. From that stock, researchers prepare the working dilutions their specific protocol calls for. Because the resulting concentration depends entirely on how much solvent is added to how much peptide, the reconstitution step is also where most avoidable measurement error is introduced if it is not done carefully.

Bacteriostatic water (BW) is sterile water for injection containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol suppresses bacterial growth after the vial septum has been punctured, which is what allows a single vial to be safely accessed multiple times over several weeks rather than needing to be discarded after one draw. This multi-draw property is why bacteriostatic water is the standard solvent choice across most peptide reconstitution protocols, including for ARA-290.

ARA-290 is a water-soluble peptide, so unlike some larger or more hydrophobic sequences it generally does not require an acidic or organic co-solvent to fully dissolve. Adding bacteriostatic water directly to the lyophilized powder is typically sufficient to bring it into solution. Researchers should still confirm solvent compatibility against the specific batch certificate of analysis or technical data sheet, since formulation details (counterion, salt form, excipients) can vary between manufacturers and synthesis runs.

Where a laboratory protocol calls for a preservative-free solution, sterile water for injection can be substituted, but because it lacks benzyl alcohol it should be treated as single-use: draw what is needed for the immediate procedure and do not plan on repeated access to the same vial over an extended period.

Maintaining sterility during reconstitution is central to producing usable, reproducible research data. Contamination introduced at this step, whether biological or particulate, can confound downstream assay results in ways that are difficult to distinguish from a genuine experimental effect. Where available, reconstitution should be performed in a biological safety cabinet or laminar flow hood using standard aseptic technique.

In practice this means working with sterile, single-use syringes and needles, swabbing the vial septum with 70% isopropyl alcohol and letting it air-dry before insertion, and avoiding any contact between ungloved hands and needles or septum surfaces. When adding bacteriostatic water to the ARA-290 vial, direct the stream along the interior glass wall rather than straight onto the powder; this reduces foaming and mechanical stress on the peptide. Swirl the vial gently after adding solvent rather than shaking it, and allow a few minutes for the powder to go fully into solution.

Once dissolved, label the vial immediately with the compound name, the calculated concentration, the preparation date, and the storage protocol being followed. Clear labeling is both a data-integrity practice and a basic laboratory safety requirement, particularly in shared research environments where more than one person may access the same freezer or refrigerator.

The relationship that governs reconstitution math is simple: concentration equals the mass of peptide divided by the volume of solvent used to dissolve it. As a conceptual illustration, if a laboratory vial contains 16 mg of lyophilized ARA-290 and the researcher reconstitutes it with 2 mL of bacteriostatic water, the resulting stock concentration is 16 mg divided by 2 mL, or 8 mg/mL.

That stock concentration is the starting point from which further dilutions are prepared to reach whatever target concentration a given in-vitro assay or preclinical protocol specifies. Because the math scales linearly, doubling the solvent volume to 4 mL against the same 16 mg would halve the concentration to 4 mg/mL, while halving the solvent to 1 mL would double it to 16 mg/mL. Researchers planning a series of working dilutions from a single stock vial should decide on the solvent volume before reconstituting, since it is far simpler to dilute a stock further than to concentrate one after the fact.

For quick reference during planning, this site companion reconstitution calculator can convert between peptide mass, solvent volume, and resulting concentration, which is useful for confirming the arithmetic before a vial is opened. As with any conceptual example, the specific mass supplied per vial and the volume chosen should always be confirmed against the batch certificate of analysis and the requirements of the experimental protocol in use.

Once in solution, ARA-290 is less stable than it was as lyophilized powder, because hydrolysis and oxidation both require an aqueous environment to proceed. For short-term laboratory use, reconstituted solutions are generally kept refrigerated at 2-8 degrees Celsius, with bacteriostatic water preservative content offering some protection against microbial growth during that window, though it does not prevent chemical degradation over time.

For longer storage, a common approach is to aliquot the reconstituted solution into small single-use volumes and freeze them at -20 degrees Celsius or below, so that each aliquot is thawed once and used rather than being repeatedly frozen and thawed. Repeated freeze-thaw cycles can promote aggregation and reduce the effective concentration of the working solution, which introduces variability into experimental results.

Reconstituted vials or aliquots should be inspected before use. A solution that has become cloudy, discolored, or shows visible particulate matter should not be used in an assay without first investigating the cause, since these are indicators of possible degradation or contamination that could affect experimental outcomes.